These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33636340)

  • 1. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases.
    Vong CT; Tseng HHL; Yao P; Yu H; Wang S; Zhong Z; Wang Y
    Drug Discov Today; 2021 Jun; 26(6):1394-1408. PubMed ID: 33636340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases.
    Seok JK; Kang HC; Cho YY; Lee HS; Lee JY
    Arch Pharm Res; 2021 Jan; 44(1):16-35. PubMed ID: 33534121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
    Wang Z; Hu W; Lu C; Ma Z; Jiang S; Gu C; Acuña-Castroviejo D; Yang Y
    Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2765-2779. PubMed ID: 30571177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors.
    Zhao N; Li CC; Di B; Xu LL
    J Autoimmun; 2020 Sep; 113():102515. PubMed ID: 32703754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Özenver N; Efferth T
    Pharmacol Res; 2021 Aug; 170():105710. PubMed ID: 34089866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.
    Lee S; Suh GY; Ryter SW; Choi AM
    Am J Respir Cell Mol Biol; 2016 Feb; 54(2):151-60. PubMed ID: 26418144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NLRP3 Inflammasome as a Pharmacological Target.
    Marchetti C
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 Inflammasome: Checkpoint Connecting Innate and Adaptive Immunity in Autoimmune Diseases.
    Zhang Y; Yang W; Li W; Zhao Y
    Front Immunol; 2021; 12():732933. PubMed ID: 34707607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLRP3: A promising therapeutic target for autoimmune diseases.
    Shen HH; Yang YX; Meng X; Luo XY; Li XM; Shuai ZW; Ye DQ; Pan HF
    Autoimmun Rev; 2018 Jul; 17(7):694-702. PubMed ID: 29729449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential.
    Su M; Wang W; Liu F; Li H
    Curr Med Chem; 2021; 28(3):569-582. PubMed ID: 31971103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLRP3 Inflammasome in Acute Myocardial Infarction.
    Mauro AG; Bonaventura A; Mezzaroma E; Quader M; Toldo S
    J Cardiovasc Pharmacol; 2019 Sep; 74(3):175-187. PubMed ID: 31356555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome.
    Zhang T; Ding S; Wang R
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibitors of the NLRP3 Inflammasome.
    Zahid A; Li B; Kombe AJK; Jin T; Tao J
    Front Immunol; 2019; 10():2538. PubMed ID: 31749805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of NLRP3 inflammasome in infection-related, immune-mediated and autoimmune skin diseases.
    Wang D; Duncan B; Li X; Shi J
    J Dermatol Sci; 2020 Jun; 98(3):146-151. PubMed ID: 32173167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
    Zhang X; Xu A; Lv J; Zhang Q; Ran Y; Wei C; Wu J
    Eur J Med Chem; 2020 Jan; 185():111822. PubMed ID: 31699536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
    Buckley LF; Libby P
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):297-305. PubMed ID: 31356538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NLRP3 inflammasome in inflammatory bowel diseases.
    Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C
    World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases.
    Sarbadhikary P; George BP; Abrahamse H
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases.
    Jiang H; Gong T; Zhou R
    Adv Immunol; 2020; 145():55-93. PubMed ID: 32081200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLRP3 inhibitors: Unleashing their therapeutic potential against inflammatory diseases.
    Ramalingam V
    Biochem Pharmacol; 2023 Dec; 218():115915. PubMed ID: 37949323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.